All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Can IPSS-R be used as a prognostic tool in HSCT in regions where molecular analysis is unavailable?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the MDS Hub was pleased to speak to Fernando Barroso Duarte, Hospital Universitário Walter Cantídio, Fortaleza, BR, and Silvia Magalhães, Universidade Federal do Ceará, Fortaleza, BR. We asked, Can the IPSS-R be used as a prognostic tool in HSCT in regions where molecular analysis is unavailable?

Can IPSS-R be used as a prognostic tool in HSCT in regions where molecular analysis is unavailable?

Barroso Duarte begins by discussing a study that enrolled 333 patients across Latin America, and how the IPSS-R affects the overall survival of patients, by comparing low-risk to high-risk patients. Magalhães goes on to mention the difficulty of accessing karyotype analysis in this region, which can affect patient outcomes. Finally, Barroso Duarte summarizes how improving access to cytogenetics will impact survival.

 

More about...